Article info
Clinical science
Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study
- Correspondence to Dr Thomas R Friberg, Retina Service, Eye and Ear Institute, Room 825, 203 Lothrop Street, Pittsburgh, PA 15213, USA; friberg{at}pitt.edu
Citation
Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study
Publication history
- Accepted February 2, 2010
- First published May 14, 2010.
Online issue publication
November 22, 2010
Article Versions
- Previous version (14 May 2010).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2010, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.